The trial, a multicenter, randomized, open-label study, compares the efficacy and safety of IBI3003 against standard-of-care regimens, specifically PVd or DPd. The primary endpoint is progression-free survival as determined by an independent review committee. This development follows promising early-stage data, where patients treated with 120 μg/kg or higher doses achieved an overall response rate of 83.3%.

Professor Peng Liu of Zhongshan Hospital, the trial's principal investigator, noted that the candidate addresses a critical gap for patients who have exhausted multiple lines of therapy. Unlike traditional treatments, IBI3003 targets GPRC5D, BCMA, and CD3 simultaneously to prevent tumor antigen escape. With Fast Track Designation already granted by the U.S. FDA, the company is positioning the drug as a next-generation immunotherapy aimed at achieving deeper and more durable responses in patients facing incurable relapse.